REGENERON PHARMACEUTICALS/ US75886F1075 /
2024-03-06 6:32:58 PM | Chg. +32.00 | Volume | Bid8:30:00 PM | Ask8:30:00 PM | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
895.00EUR | +3.71% | 4 Turnover: 3,580 |
-Bid Size: - | -Ask Size: - | 99.25 bill.EUR | - | - |
GlobeNewswire
7:45 PM
More than $9 Million Awarded to High School Scientists and Engineers at the Regeneron International ...
GlobeNewswire
05-14
Veru Announces Mitchell Steiner as Keynote Speaker at Biomed Israel 2024: The 22nd National Life Sci...
GlobeNewswire
05-13
Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of Adolescents with Chroni...
GlobeNewswire
05-10
Prime Medicine Reports First Quarter 2024 Financial Results and Provides Business Updates
GlobeNewswire
05-09
Intellia Therapeutics Announces First Quarter 2024 Financial Results and Highlights Recent Company P...
GlobeNewswire
05-08
Latest DB-OTO Results Show Dramatically Improved Hearing to Normal Levels in a Child with Profound G...
GlobeNewswire
05-07
Kiniksa Pharmaceuticals to Present at Bank of America Securities 2024 Health Care Conference
GlobeNewswire
04-29
EYLEA® HD (aflibercept) Injection 8 mg Presentations at ARVO Reinforce Sustained and Clinically Mean...
GlobeNewswire
04-25
Regeneron and Mammoth Biosciences Collaborate to Pursue Next-Generation CRISPR-Based Gene Editing fo...
GlobeNewswire
04-24
Regeneron to Showcase Progress in Advancing Novel Investigational Treatment Approaches for a Broad R...
GlobeNewswire
04-23
Kiniksa Pharmaceuticals Reports First Quarter 2024 Financial Results and Recent Portfolio Execution
GlobeNewswire
04-22
Regeneron to Highlight Advances in Genetic Medicine Research at American Society of Gene and Cell Th...
GlobeNewswire
04-18
Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Regeneron Pharmaceuticals,...
GlobeNewswire
04-18
REGENERON ALERT: Bragar Eagel & Squire, P.C. is Investigating Regeneron Pharmaceuticals, Inc. on Beh...
GlobeNewswire
04-16
Kiniksa Pharmaceuticals to Report First Quarter 2024 Financial Results on April 23, 2024
GlobeNewswire
04-16
Ocular Therapeutix™ Strengthens Clinical Team with Appointment of Key Retinal Leaders
GlobeNewswire
04-15
Regeneron Ventures Launches with $500 Million Commitment to Fuel Promising Biotechnology Innovation
GlobeNewswire
04-11
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Regeneron Phar...